SCHEMBL1135458

SCHEMBL1135458

CC(Br)C(=O)C(F)(F)F

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14215823 0.75 CA2 (0.38)
SCHEMBL216366 0.75
SCHEMBL26089487 0.75 ALDH1A1 (0.39)
SCHEMBL800660 0.75
SCHEMBL19090272 0.73
SCHEMBL21375210 0.73
SCHEMBL6218904 0.73
Water SCHEMBL21725015 0.73 ALDH1A1 (0.37)
SCHEMBL6906960 0.73
SCHEMBL12310674 0.73

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 163 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250059189-A1 PYRIDINE DERIVATIVES AND THEIR USE AS SODIUM CHANNEL ACTIVATORS XENON PHARMACEUTICALS INC. (CA) 2025-02-20 US disclosed
US-12054486-B2 Pyridine derivatives and their use as sodium channel activators XENON PHARMACEUTICALS INC. (CA) 2024-08-06 US disclosed
EP-4405347-A1 PYRIDINE DERIVATIVES AND THEIR USE AS SODIUM CHANNEL ACTIVATORS Xenon Pharmaceuticals Inc. (CA) 2024-07-31 EP disclosed
US-20240208961-A1 EIF4E INHIBITORS AND USES THEREOF PIC Therapeutics, Inc. 2024-06-27 US disclosed
US-20240208961-A1 EIF4E INHIBITORS AND USES THEREOF PIC Therapeutics, Inc. 2024-06-27 US disclosed
WO-2024099398-A1 CLASS OF SULFONAMIDE COMPOUNDS CONTAINING ORTHO-FUSED HETEROCYCLE AND USE THEREOF 南京明德新药研发有限公司 2024-05-16 WO disclosed
US-20230144095-A1 PYRIDINE DERIVATIVES AND THEIR USE AS SODIUM CHANNEL ACTIVATORS X-CHEM GLOBAL HQ 2023-05-11 US disclosed
WO-2023049364-A1 PYRIDINE DERIVATIVES AND THEIR USE AS SODIUM CHANNEL ACTIVATORS XENON PHARMACEUTICALS INC. (CA) 2023-03-30 WO disclosed
US-10618893-B2 GPR120 agonists for the treatment of type II diabetes JANSSEN PHARMACEUTICALS NV (BE) 2020-04-14 US disclosed
CN-106414434-B Isothiazole derivatives as GPR120 agonists for the treatment of type II diabetes 詹森药业有限公司 2019-12-31 CN disclosed
US-20060167009-A1 Monocyclic substituted phenyl methanones F. HOFFMANN-LA ROCHE AG (CH) 2006-07-27 US disclosed
WO-2006072436-A1 [4-(HETEROARYL) PIPERAZIN-1-YL]-(2,5-SUBSTITUTED -PHENYL)METHANONE DERIVATIVES AS GLYCINE TRANSPORTER 1 (GLYT-1) INHIBITORS FOR THE TREATMENT OF NEUROLOGICAL AND NEUROPSYCHIATRIC DISORDERS F. HOFFMANN-LA ROCHE AG (CH) 2006-07-13 WO disclosed
US-20060094708-A1 to treat cellular proliferative diseases, hyperplasias, solid tumor, cardiac hypertrophy, immune disorders and inflammation; modulators of one or more mitotic kinesins; N-(2-(2-dimethylamino-acetylamino)-1-{4-[8-(1-hydroxy-ethyl)-imidazo[1,2-a]pyridin-2-yl]-benzyl}-ethyl)-3-chloro-4-isopropoxy-benzamide CYTOKINETICS, INCORPORATED 2006-05-04 US disclosed
CN-1252066-C Pyridazine-3-one derivatives, their use, and intermediate preparing them SUMITOMO CHEMICAL CO (JP) 2006-04-19 CN disclosed
WO-2005107762-A2 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS CYTOKINETICS, INC. (US) 2005-11-17 WO disclosed
CN-1491949-A Pyridazine-3-one derivatives, their use, and intermediate preparing them ס�ѻ�ѧ��ҵ��ʽ���� 2004-04-28 CN disclosed
CN-1117083-C Pyridazin-3-one derivatives, their use, and intermediates for their preparation SUMITOMO CHEMICAL CO (JP) 2003-08-06 CN disclosed
US-6515124-B2 (Z)-2-((2-bromo-4-(((3-hydroxybenzyl)amino)carbonyl)benzoyl) -amino)pent-2-enoic acid, for example; useful for treating psoriasis HOFFMAN-LA ROCHE INC. 2003-02-04 US disclosed
US-20020161237-A1 Dehydroamino acids HOFFMANN-LA ROCHE INC. 2002-10-31 US disclosed
CN-1202157-A Pyridazin-3-one derivatives, their use, and intermediates for their preparation SUMITOMO CHEMICAL CO (JP) 1998-12-16 CN disclosed